Summary
This study sought to evaluate the changes in direct medical costs and life-years gained or lost by adding enalapril to conventional treatment (digoxin and diuretics) for heart failure (HF).
The published results of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial, and a decision analytical model developed by the University of Pennsylvania, were used in combination with New Zealand data to undertake the evaluation. All costs were measured in 1993 New Zealand dollars ($NZ) [$NZ1 = $US0.5509, September 1993].
Potential net cost savings per patient treated over a 4-year period were $NZ652 together with an additional 2 months of life gained. If these individual potential cost savings are extended to the New Zealand population who have HF (but are at present not receiving an ACE inhibitor) then $NZ6 517 000 in discounted health sector costs could be avoided.
The model was sensitive to changes in the price of enalapril, to estimates of the population with HF, the percentage of the population with HF treated with enalapril, and to hospital unit costs for nonfatal cases of HF. The study demonstrated that the addition of enalapril to the conventional treatment of HF was cost effective when compared with conventional medical therapy alone.
Similar content being viewed by others
References
van Hout BA, Wielink G, Bonsel GJ, et al. Effects of ACE inhibitors on heart failure in The Netherlands. PharmacoEconomics 1993 May; 3(5): 387–97
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35
Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. (V-HeFT II). N Engl J Med 1991; 325: 303–10
International Classification of Diseases. 9th rev. ed. Clinical Modification (ICD-9CM). Ann Arbor (MI): WHO, 1978
Ministry of Health. Mortality and demographic data 1992. Wellington: Ministry of Health, 1994
Ministry of Health. Hospital and selected morbidity data 1992. Wellington: Ministry of Health, 1981–93
McKendry CG, Muthumala D. Health expenditure trends in New Zealand: update to 1993 [appendix 2A]. Wellington: Ministry of Health, 1994
Doughty R, Yee T, Sharpe N, et al. Hospital admissions and deaths due to congestive heart failure in New Zealand, 1988–1991. NZ Med J 1995; 108(1012): 473–6
Wild CJ, Seber GAF. Introduction to probability and statistics. Auckland: Department of Statistics, Auckland University, 1995
Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951–7
Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301–6
Taylor Nelson Cardiomonitor — New Zealand, Autumn 1993. Epsom, Surrey: Taylor Nelson Healthcare, 1993
Pricing schedules: 1 September 1993. Wellington: Ministry of Health, 1993: 59
Core health and disability support services for 1993/94. First report of the National Advisory Committee on Core Health and Disability Support Services [appendix 6]. Wellington: National Advisory Committee on Core Health and Disability Support Services, 1992
Scott WG, Scott HM. Ischaemic stroke in New Zealand: an economic study. NZ Med J 1994; 107: 443–6
Scott WG, McKendry CG, Scott HM. Methodologies for economic evaluation of high technology in health care. Wellington: Department of Health, 1992
Scott WG, White HD, Scott HM. Cost of coronary heart disease in New Zealand. N Z Med J 1993; 106: 347–9
Wilde MI, Bryson HM, Goa KL. Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension. PharmacoEconomics 1994; 6: 155–82
Statistics New Zealand. Personal Computer Information Network for Official Statistics: a computerised database of official statistics for New Zealand and programme for manipulation and analysis of statistical series (PC INFOS). Wellington: Statistics New Zealand, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scott, W.G., Scott, H.M. Heart Failure. Pharmacoeconomics 9, 156–167 (1996). https://doi.org/10.2165/00019053-199609020-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199609020-00007